IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-024-55614-y.html
   My bibliography  Save this article

Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma

Author

Listed:
  • Matías S. Mendeville

    (location VUmc)

  • Jurriaan Janssen

    (location VUmc)

  • G. Tjitske Los-de Vries

    (location VUmc)

  • Erik Dijk

    (location VUmc)

  • Julia Richter

    (Campus Kiel)

  • Marcel Nijland

    (University Medical Centre Groningen)

  • Margaretha G. M. Roemer

    (location VUmc)

  • Phylicia Stathi

    (location VUmc)

  • Nathalie J. Hijmering

    (location VUmc
    Amsterdam University Medical Centre)

  • Reno Bladergroen

    (location VUmc)

  • Diego A. Pelaz

    (location VUmc)

  • Arjan Diepstra

    (University Medical Centre Groningen)

  • Corinne J. Eertink

    (location VUmc)

  • Coreline N. Burggraaff

    (location VUmc)

  • Yongsoo Kim

    (location VUmc)

  • Pieternella J. Lugtenburg

    (University Medical Center Rotterdam)

  • Anke Berg

    (University Medical Centre Groningen)

  • Alexandar Tzankov

    (University of Basel and University Hospital Basel)

  • Stefan Dirnhofer

    (University of Basel and University Hospital Basel)

  • Ulrich Dührsen

    (University Hospital Essen)

  • Andreas Hüttmann

    (University Hospital Essen)

  • Wolfram Klapper

    (Campus Kiel)

  • Josée M. Zijlstra

    (location VUmc)

  • Bauke Ylstra

    (location VUmc)

  • Daphne Jong

    (location VUmc)

Abstract

Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index. For all subtypes, adverse prognostic value of i/eot-PET-positive status is confirmed. Consistent with frequent primary refractory disease, only 67% C2 patients become eot-PET-negative versus 81-88% for other subtypes. Indicative of high relapse rates, outcome of C5 i/eot-PET-negative patients remains significantly worse in HOVON-84, which trend validates in the PETAL and SAKK38-07 trials (NCT00544219). These results show the added value of integrated genetic subtyping and PET monitoring for prognostic stratification and subtype-specific trial design.

Suggested Citation

  • Matías S. Mendeville & Jurriaan Janssen & G. Tjitske Los-de Vries & Erik Dijk & Julia Richter & Marcel Nijland & Margaretha G. M. Roemer & Phylicia Stathi & Nathalie J. Hijmering & Reno Bladergroen & , 2025. "Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma," Nature Communications, Nature, vol. 16(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-024-55614-y
    DOI: 10.1038/s41467-024-55614-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-55614-y
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-55614-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-024-55614-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.